Realcan(SZ:002589)2022-12-07 09:46Group 1: Company Growth - Revenue reached 5.602 billion yuan, with a net profit of 129 million yuan, representing year-on-year growth of 27.30% and 29.58% respectively [1] - The growth in pharmaceutical sales is attributed to the improvement of the company's sales network and strong terminal coverage capabilities [1] Group 2: Profitability Metrics - Gross profit margin increased by 0.47 percentage points due to a higher proportion of high-margin consumable distribution business [1] - Selling expense ratio rose by 0.35 percentage points to 5.11%, driven by increased sales expenses corresponding to revenue growth and expansion in the medical device business [1] Group 3: Management Expenses - Management expense ratio increased by 0.22 percentage points to 1.66%, attributed to the expansion of logistics personnel and depreciation from the Jinan and Yantai pharmaceutical modern logistics projects reaching operational status [2] Group 4: Coverage and Network - The company boasts the most comprehensive sales network in the province, with coverage rates exceeding 98% for large hospitals and 95% for grassroots medical institutions, achieving 100% coverage for tertiary hospitals [2] - Through distribution clients, the company has achieved coverage in hospitals and retail markets not directly covered in the province [2]